Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity

被引:186
作者
Romero, Roberto [1 ,2 ,3 ,4 ,5 ]
Erez, Offer [1 ,2 ,6 ,7 ]
Huttemann, Maik [5 ]
Maymon, Eli [1 ,2 ,6 ,7 ]
Panaitescu, Bogdan [1 ,2 ,6 ]
Conde-Agudelo, Agustin [1 ,2 ]
Pacora, Percy [1 ,2 ,6 ]
Yoon, Bo Hyun [8 ]
Grossman, Lawrence I. [5 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Program Perinatal Res & Obstet, Div Intramural Res,NIH,US Dept HHS,NICHD, Bethesda, MD 20892 USA
[2] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Program Perinatal Res & Obstet, Div Intramural Res,NIH,US Dept HHS,NICHD, Detroit, MI 20892 USA
[3] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA
[4] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA
[5] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48202 USA
[6] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA
[7] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Univ Med Ctr, Dept Obstet & Gynecol,Sch Med, Beer Sheva, Israel
[8] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea
关键词
fms-like tyrosine kinase-1 (sFlt-1); insulin resistance; large for gestational age (LGA); mTOR; macrosomia; mitochondria; nutritional sensing; obesity; placental growth factor (PlGF); soluble endoglin (sEng); soluble vascular endothelial growth factor receptor-1 (sVEGFR-1); POLYCYSTIC-OVARY-SYNDROME; ANTI-ANGIOGENIC FACTORS; PLACENTAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR-1 CONCENTRATION; MATERNAL PLASMA-CONCENTRATIONS; ELEVATED LIVER-ENZYMES; OBESE PREGNANT-WOMEN; LOW PLATELET COUNT; LACTIC-ACIDOSIS;
D O I
10.1016/j.ajog.2017.06.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Metformin is everywhere. Originally introduced in clinical practice as an antidiabetic agent, its role as a therapeutic agent is expanding to include treatment of prediabetes mellitus, gestational diabetes mellitus, and polycystic ovarian disease; more recently, experimental studies and observations in randomized clinical trials suggest that metformin could have a place in the treatment or prevention of preeclampsia. This article provides a brief overview of the history of metformin in the treatment of diabetes mellitus and reviews the results of metaanalyses of metformin in gestational diabetes mellitus as well as the treatment of obese, non-diabetic, pregnant women to prevent macrosomia. We highlight the results of a randomized clinical trial in which metformin administration in early pregnancy did not reduce the frequency of large-for-gestational-age infants (the primary endpoint) but did decrease the frequency of preeclampsia (a secondary endpoint). The mechanisms by which metformin may prevent preeclampsia include a reduction in the production of antiangiogenic factors (soluble vascular endothelial growth factor receptor-1 and soluble endoglin) and the improvement of endothelial dysfunction, probably through an effect on the mitochondria. Another potential mechanism whereby metformin may play a role in the prevention of preeclampsia is its ability to modify cellular homeostasis and energy disposition, mediated by rapamycin, a mechanistic target. Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta. There is considerable evidence to suggest that this agent is safe during pregnancy. New literature on the role of metformin as a chemotherapeutic adjuvant in the prevention of cancer and in prolonging life and protecting against aging is reviewed briefly. Herein, we discuss the mechanisms of action and potential benefits of metformin.
引用
收藏
页码:282 / 302
页数:21
相关论文
共 277 条
  • [1] Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review
    Abildgaard, Ulrich
    Heimdal, Ketil
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2013, 166 (02) : 117 - 123
  • [2] Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes
    Adekola, Henry
    Romero, Roberto
    Chaemsaithong, Piya
    Korzeniewski, Steven J.
    Dong, Zhong
    Yeo, Lami
    Hassan, Sonia S.
    Chaiworapongsa, Tinnakorn
    [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2015, 28 (14) : 1621 - 1632
  • [3] Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats
    Afzal, Muhammad
    Kazmi, Imran
    Gupta, Gaurav
    Rahman, Mahfoozur
    Kimothi, Vishwadeepak
    Anwar, Firoz
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2012, 20 (04) : 365 - 370
  • [4] Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country. A randomized control trial
    Ainuddin, Jahanara
    Karim, Nasim
    Hasan, Anjum Ara
    Naqvi, Sanower Ali
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 107 (02) : 290 - 299
  • [5] Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia
    Akolekar, R.
    Zaragoza, E.
    Poon, L. C. Y.
    Pepes, S.
    Nicolaides, K. H.
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 32 (06) : 732 - 739
  • [6] 4. Prevention or Delay of Type 2 Diabetes
    不详
    [J]. DIABETES CARE, 2016, 39 : S36 - S38
  • [7] Recurrence of ischemic placental disease
    Ananth, Cande V.
    Peltier, Morgan R.
    Chavez, Martin R.
    Kirby, Russell S.
    Getahun, Darios
    Vintzileos, Anthony M.
    [J]. OBSTETRICS AND GYNECOLOGY, 2007, 110 (01) : 128 - 133
  • [8] Ischemic placental disease: epidemiology and risk factors
    Ananth, Cande V.
    Vintzileos, Anthony M.
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 159 (01) : 77 - 82
  • [9] Do metformin a real anticarcinogen? A critical reappraisal of experimental data
    Anisimov, Vladimir N.
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (06)
  • [10] If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice
    Anisimov, Vladimir N.
    Berstein, Lev M.
    Popovich, Irina G.
    Zabezhinski, Mark A.
    Egormin, Peter A.
    Piskunova, Tatiana S.
    Semenchenko, Anna V.
    Tyndyk, Margarita L.
    Yurova, Maria N.
    Kovalenko, Irina G.
    Poroshina, Tatiana E.
    [J]. AGING-US, 2011, 3 (02): : 148 - 157